[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie (ABBV) shares rallied sharply on Monday after the pharmaceutical behemoth announced a definitive agreement to acquire Apogee Therapeutics (APGE) for about $10.9 billion.

The all-cash transaction will see ABBV purchase all outstanding APGE shares for just over $135 each, which translates to a 50% premium on their previous close. 

Fundamentals

See More
  • Market Capitalization, $K 556,765,184
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.26
  • Price/Sales 5.84
  • Price/Cash Flow 16.18
  • Price/Book 6.77

Options Overview Details

View History
  • Implied Volatility 24.77% (-0.89%)
  • Historical Volatility 21.11%
  • IV Percentile 86%
  • IV Rank 70.69%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 3) 4.51 (1.95%)
  • Put/Call Vol Ratio 0.30
  • Today's Volume 20,784
  • Volume Avg (30-Day) 24,028
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 323,623
  • Open Int (30-Day) 362,338
  • Expected Range 226.78 to 235.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 7
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.84 +4.73%
on 06/01/26
241.60 -4.27%
on 06/11/26
-3.05 (-1.30%)
since 05/22/26
3-Month
220.37 +4.96%
on 05/11/26
247.21 -6.44%
on 04/02/26
-4.08 (-1.73%)
since 03/20/26
52-Week
149.74 +54.46%
on 06/23/25
251.71 -8.11%
on 03/02/26
+81.50 (+54.41%)
since 06/20/25

Most Recent Stories

More News
The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

APGE : 132.55 (+46.66%)
JNJ : 231.29 (+1.27%)
LLY : 1,102.08 (+0.32%)
ABBV : 230.01 (+6.25%)
REGN : 612.50 (+0.42%)
SNY : 41.78 (-1.42%)
3 Best ETFs to Kick Volatility to the Curb

Low- and minimum-volatility ETFs can help investors fade turbulence in the markets while still participating in upside.

SPLV : 73.24 (+0.21%)
VFMV : 139.23 (+0.11%)
KO : 79.53 (+0.18%)
JNJ : 231.29 (+1.27%)
CNQ : 41.79 (+1.80%)
LVHI : 40.66 (+0.27%)
RIO : 99.36 (-0.72%)
SHEL : 79.66 (+1.08%)
DUK : 123.52 (-0.27%)
FE : 46.76 (+0.67%)
How to Hunt for Mega-Cap Value After the SpaceX IPO

I'm not buying into SpaceX following the record-setting IPO. But I am looking for big value elsewhere. Here's how I start my search.

GOOG : 348.78 (-5.08%)
GOOGL : 349.68 (-4.99%)
SPCX : 154.60 (-16.43%)
$SPX : 7,472.79 (unch)
BRK.A : 734,400.00 (+0.11%)
JPM : 331.48 (+1.92%)
BRK.B : 488.69 (-0.16%)
JNJ : 231.29 (+1.27%)
TOPT : 33.05 (-0.66%)
$IUXX : 30,347.08 (unch)
AMZN : 232.79 (-4.75%)
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

HUM : 360.72 (+0.02%)
JNJ : 231.29 (+1.27%)
LLY : 1,102.08 (+0.32%)
DXCM : 69.07 (-4.69%)
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience,...

JNJ : 231.29 (+1.27%)
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

STOCKHOLM , June 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced results from the investigational Phase 3 MonumenTAL-3 study...

JNJ : 231.29 (+1.27%)
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. ...

JNJ : 231.29 (+1.27%)
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

STOCKHOLM , June 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY ® (nipocalimab-aahu) produced a...

JNJ : 231.29 (+1.27%)
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results

Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.

IDYA : 34.23 (+9.61%)
JNJ : 231.29 (+1.27%)
INCY : 103.66 (+5.54%)
TNGX : 28.50 (+1.89%)
RHHBY : 49.1200 (-1.25%)
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers Acquisition adds a proprietary degrader antibody conjugate...

JNJ : 231.29 (+1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 236.61
2nd Resistance Point 234.03
1st Resistance Point 232.66
Last Price 231.29
1st Support Level 228.71
2nd Support Level 226.13
3rd Support Level 224.76

See More

52-Week High 251.71
Last Price 231.29
Fibonacci 61.8% 212.76
Fibonacci 50% 200.73
Fibonacci 38.2% 188.69
52-Week Low 149.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.